Neuritin: The Protein That Restrains Allergy and Autoimmune Antibodies

Facebook ↗WhatsApp ↗

Originally published 2021-03-17.

Neuritin Research Explored a Possible Route to Controlling Immune Responses

Image: a human plasma cell, the type of immune cell that makes antibodies. Photo by Steve Gschmeissner/Science Photo Library/Getty Images.

In March 2021 a team at the Australian National University (ANU) reported that a protein called neuritin acts as a natural brake on the immune system, restraining the cells that produce harmful antibodies in allergies and autoimmune disease. The study, published in the journal Cell, was done in mice and in human tonsil cells grown in the lab. It does not mean a neuritin treatment exists, but it pointed to a new way of thinking about how the body keeps its antibody responses in check.

Below is what the researchers found, how it fits into what we already know about allergy and autoimmunity, what the study did not show, and why the gap between a mouse result and a medicine is usually measured in years.

The short answer: what neuritin does

Antibodies are made by plasma cells, which develop from B cells. Usually they target viruses and bacteria. Sometimes, though, the process goes wrong: plasma cells appear that make antibodies against the body’s own tissues, the hallmark of many autoimmune diseases, or that make large amounts of IgE, the antibody class behind allergic reactions.

The ANU team, led by first author Paula Gonzalez-Figueroa and senior author Carola Vinuesa, found that a small group of immune cells called T follicular regulatory (Tfr) cells produce neuritin, and that neuritin acts directly on B cells to stop these rogue plasma cells from forming. In their words, reported by ScienceAlert, Gonzalez-Figueroa said the protein suppresses formation of rogue plasma cells. Neuritin had mostly been studied in the nervous system, where it helps nerve cells grow, so finding it at work in immune regulation was a surprise.

How the experiments worked

The researchers used genetically modified mice and cultures of human tonsil cells. Tonsils are a convenient source of human immune tissue because they contain the germinal centres where B cells mature, and they are routinely removed in surgery.

Mice bred so that their Tfr cells could not make neuritin developed two problems. Early in life they produced plasma cells that attacked their own tissues. And when they were sensitised to egg albumin, a common laboratory allergen, they were more likely to die from anaphylaxis, the most severe form of allergic reaction, because they made too much IgE. When the team gave these mice neuritin, the faulty plasma cells largely disappeared and the animals appeared healthy.

The human tonsil experiments showed that neuritin had a similar restraining effect on human B cells in the dish. That is useful evidence that the mechanism is not unique to mice, but it is not the same as testing the protein in people.

The study took around five years. The authors said much remained to be worked out, including exactly how neuritin is released, which receptor it acts through on B cells and whether it affects other processes in the body.

Why it caught attention

Most current treatments for autoimmune disease act broadly. Steroids and other immunosuppressants calm the whole immune system, and some newer drugs wipe out large populations of B cells. These can work well, but they raise the risk of infection and come with other side effects. Allergy treatment, meanwhile, mostly relieves symptoms after the immune reaction has started.

The appeal of neuritin is that it seems to target only the problem cells. Vinuesa told ScienceAlert that if the approach worked, doctors would not need to deplete important immune cells or dampen the whole immune system, but could instead use a protein the body already relies on to maintain tolerance. She described it as potentially a completely new approach rather than simply another drug. (Some reports at the time credited that comment to Gonzalez-Figueroa; ScienceAlert attributes it to Vinuesa.)

The potential reach is large. More than 80 autoimmune diseases are recognised, from type 1 diabetes and rheumatoid arthritis to lupus and multiple sclerosis, and estimates suggest they affect roughly 5 to 10 percent of people in Western countries, about four in five of them women. Allergies are even more common.

Myth check: histamine, T cells and “built-in antihistamines”

Some early coverage of this study described allergies and autoimmune disease as being caused by T cells releasing histamine, with neuritin acting like a built-in antihistamine. That is not how it works, and it is not what the paper claimed.

Histamine is released mainly by mast cells and basophils. In an allergy, IgE antibodies sit on the surface of mast cells; when the allergen arrives and binds to them, the mast cells burst open and release histamine and other chemicals that cause swelling, itching and, in severe cases, anaphylaxis. Antihistamines block histamine after it is released. Neuritin works much further upstream, by limiting the production of the IgE-making plasma cells in the first place. Autoimmune disease is different again: it is driven largely by antibodies and immune cells that attack the body’s own tissues, not by histamine.

What the study did not show

It is easy to read a headline about a protein that “stops allergies” and assume a cure is close. It is worth being precise:

  • No human treatment was tested. All the in-body experiments were in mice. Many promising results in mice never translate into safe, effective medicines.
  • Proteins are hard to use as drugs. They must be manufactured reliably, delivered to the right tissue and dosed without triggering an immune reaction of their own.
  • Safety is unknown. Because neuritin also acts in the nervous system, researchers would need to check for unwanted effects elsewhere.
  • Not every condition is the same. Autoimmune diseases have different causes, and not all of them are driven mainly by antibodies, so a single approach is unlikely to fit all.

If you live with an allergy or autoimmune condition, this research does not change current treatment. Talk to a doctor about any changes to your care.

Where the research stands

The 2021 paper is best seen as a piece of basic science that answered a long-standing question: how Tfr cells, known to suppress unwanted antibody responses, actually do it. Identifying neuritin as one of their tools gives researchers a specific molecule to study, measure and possibly mimic.

Vinuesa, a Spanish-born immunologist known for her work on the genetics of autoimmune disease, moved from ANU to the Francis Crick Institute in London in 2022 and continues to lead research groups in both countries. Any path from here to a medicine would run through further animal studies, work on how to produce and deliver the protein, and eventually carefully staged clinical trials. That process typically takes a decade or more, and most candidates drop out along the way. Still, finding the body’s own off-switch for harmful antibodies is the kind of discovery that later treatments are built on.

Sources: ScienceAlert, 11 March 2021: Our bodies do have a natural answer for killer allergies and autoimmune diseases; Gonzalez-Figueroa P. et al., Cell, 2021, doi: 10.1016/j.cell.2021.02.027; Wikipedia: Carola Vinuesa; Wikipedia: Autoimmune disease; Wikipedia: Mast cell.

COMMENTS